Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $93.1 million.

  • Phathom Pharmaceuticals' Total Current Liabilities rose 4263.42% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 4263.42%. This contributed to the annual value of $85.7 million for FY2024, which is 12105.67% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Total Current Liabilities stood at $93.1 million, which was up 4263.42% from $91.8 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Total Current Liabilities' 5-year high stood at $93.1 million during Q3 2025, with a 5-year trough of $11.4 million in Q1 2022.
  • Moreover, its 4-year median value for Total Current Liabilities was $38.8 million (2023), whereas its average is $45.4 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 223.01% in 2023, then soared by 20090.01% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Total Current Liabilities (Quarter) stood at $26.2 million in 2022, then skyrocketed by 47.81% to $38.8 million in 2023, then surged by 121.06% to $85.7 million in 2024, then increased by 8.63% to $93.1 million in 2025.
  • Its Total Current Liabilities was $93.1 million in Q3 2025, compared to $91.8 million in Q2 2025 and $74.0 million in Q1 2025.